Halozyme Therapeutics, Inc. (HALO)
71.82
-1.14
(-1.56%)
USD |
NASDAQ |
Jan 15, 16:00
71.84
+0.02
(+0.03%)
After-Hours: 07:05
Halozyme Therapeutics SG&A Expense (TTM): 172.31M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Johnson & Johnson | 23.38B |
| Merck & Co., Inc. | 10.70B |
| AIM ImmunoTech, Inc. | 10.06M |
| Stryker Corp. | 8.547B |
| Skye Bioscience, Inc. | 16.93M |